Strategy for developing a genetically-engineered whole-virus vaccine against HIV.
The production of genetically-engineered, noninfectious virions of human immunodeficiency virus (HIV) represents a novel approach to the development of a safe and effective vaccine for the acquired immune deficiency syndromes (AIDS). Insofar as preparations of inactivated simian immunodeficiency virus (SIV) are now demonstrating protection in immunization-challenge studies in rhesus monkeys, a safe preparation of noninfectious HIV virions produced in a genetically-engineered cell line becomes a logical candidate vaccine for studies in humans. These particles, or pseudovirions, offer distinct advantages over the use of inactivated HIV for human AIDS vaccines. Guarantees of safety without the requirement for inactivation and their potential for structural modification for the modulation of immunogenicity are compelling reasons for the acceptance of HIV pseudovirions as a candidate vaccine in humans.
Haynes
J R
JR
Connaught Centre for Biotechnology Research, Willowdale, Ontario, Canada.
Yao
F L
FL
Ma
J
J
Cao
S X
SX
Klein
M H
MH
D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D000818:Animals; D002460:Cell Line; D002522:Chlorocebus aethiops; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D006801:Humans; D014614:Vaccines, Synthetic / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology*
D014614:Vaccines, Synthetic; D014765:Viral Vaccines